Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG401 in metastatic triple-negative breast cancer
NCT06732323Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ESG401 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Progression-Free Survival at 28 months and Overall Survival at 41 months. Started Sep 2025; status: recruiting.
02
Drugs
ESG401
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06732323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732323.